Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Sprint Bioscience AB (SPRINT) Stock Price & Analysis

1 Followers

SPRINT Stock Chart & Stats

kr 4.00kr 0.35(9.59%)
At close: 5:30 PM GMT+1
kr 3kr 3.5kr 4Aug 10Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2
Day’s Range
SEK 3.55 - SEK 4.00
52-Week Range
SEK 0.58 - SEK 4.59
Previous Close
SEK 3.65
Volume
N/A
Average Volume (3M)
249.94K
Market Cap
SEK 422.06M
Enterprise Value
SEK 343.57M
Total Cash (Recent Filing)
SEK 93.26M
Total Debt (Recent Filing)
SEK 0
Price to Earnings (P/E)
5.6
Beta
1.49
Next Earnings
Nov 11, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

A debt-free balance sheet limits interest burden and financial risk, while the substantial rebuilding of equity provides a stronger capital base. This gives Sprint Bioscience greater flexibility to fund discovery activities and withstand periods of uneven operating performance.

Strong Current Profitability

The current margin profile shows that recent revenue is converting into substantial earnings, with both gross and net profitability at strong levels. If sustained, this improves internal funding capacity and supports continued investment in the company’s drug-discovery pipeline.

High-Quality Cash Generation

Operating and free cash flow closely tracking net income indicates strong recent earnings quality rather than profits unsupported by cash. This strengthens the company’s ability to finance operations internally and reduces reliance on external capital during the coming quarters.

Bears Say

Recent Revenue Decline

The recent top-line contraction indicates that strong margins have not been matched by consistent revenue expansion. Continued revenue volatility could reduce operating leverage, make earnings less predictable, and limit the resources available for advancing multiple discovery programs.

Cyclical Profitability History

The sharp swing from earlier losses to very high recent returns suggests that profitability has been cyclical rather than consistently established. Such variability makes future earnings power harder to forecast and increases dependence on successful performance in individual periods.

Volatile Cash Generation

Although current cash generation is strong, the history of materially negative cash flow shows that funding capacity can change substantially between periods. Even the recent free-cash-flow decline reinforces the risk that internal financing may not remain stable over time.

SPRINT FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?
Sprint Bioscience AB lowest stock price was kr 0.58 and its highest was kr 4.59 in the past 12 months.
What is Sprint Bioscience AB’s market cap?
Sprint Bioscience AB’s market cap is kr 422.06M.
When is Sprint Bioscience AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sprint Bioscience AB’s earnings last quarter?
Sprint Bioscience AB released its earnings results on Aug 26, 2026. The company reported -kr 0.154 earnings per share for the quarter.
Is Sprint Bioscience AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Sprint Bioscience AB pay dividends?
Sprint Bioscience AB does not currently pay dividends.
What is Sprint Bioscience AB’s EPS estimate?
Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sprint Bioscience AB have?
Sprint Bioscience AB has 105,515,540 shares outstanding.
What happened to Sprint Bioscience AB’s price movement after its last earnings report?
Sprint Bioscience AB reported an EPS of -kr 0.154 in its last earnings report. Following the earnings report the stock price went up 1.905%.
Which hedge fund is a major shareholder of Sprint Bioscience AB?
Currently, no hedge funds are holding shares in SE:SPRINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology